{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-22-000048","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.098440+00:00","generated_at":"2026-06-24T01:48:30.024409+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Halozyme Q2 revenue up 12% to $152.4M, raises FY22 revenue guidance to $655-685M","bullets":["GAAP diluted EPS $0.16; non-GAAP diluted EPS $0.53. Royalty revenue $85.3M (+86% YoY).","FY22 guidance raised: total revenue $655-685M (prior $530-560M); non-GAAP EPS $2.10-2.25.","Antares Pharma acquisition closed May 2022; expected to add $115-125M revenue in FY22.","Operating income $34.1M vs $93.0M in Q2 2021, reflecting Antares-related transaction costs.","Cash and marketable securities $209.4M on June 30, 2022, down from $740.9M at Dec 31, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-22-000048","json":"https://secwatch.observer/filing/0001159036-22-000048.json","markdown":"https://secwatch.observer/filing/0001159036-22-000048.md","text":"https://secwatch.observer/filing/0001159036-22-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000048/0001159036-22-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903622000048/halo-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:48:30.024409+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}